Literature DB >> 24816477

Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome.

Daniel Varon1, Warren Barker, David Loewenstein, Maria Greig, Adriana Bohorquez, Isael Santos, Qian Shen, Molly Harper, Tatiana Vallejo-Luces, Ranjan Duara.   

Abstract

OBJECTIVE: This study aims to determine the clinical utility of visual ratings and volumetric measurements of medial temporal atrophy among subjects from the Alzheimer's Disease Neurorimaging Initiative (ADNI) cohort.
METHODS: A sample of 189 subjects from the ADNI, Phase 1 (ADNI-1), was chosen as follows: 49 cognitively normal (CN), 89 with mild cognitive impairment (MCI), and 50 with Alzheimer's disease (AD). Structural MRI images were downloaded from the ADNI website, and a visual rating system (VRS) was used to obtain semi-quantitative ratings of the hippocampus (HPC) and entorhinal cortex (ERC). VRS ratings and FreeSurfer measures of the HPC and ERC were used to predict (i) baseline diagnosis and (ii) progression to AD among subjects with MCI at baseline.
RESULTS: VRS and FreeSurfer measures of ERC were equivalent in classifying subjects at baseline, but FreeSurfer measures of HPC were superior to VRS measures for classifying CN versus MCI subjects. VRS and FreeSurfer measures of both HPC and ERC were significant predictors of progression from MCI to AD. However, VRS ratings of ERC were superior to other MRI measures. MCI subjects with minimal ERC atrophy by VRS had a threefold lower progression rate to AD at 3.2 years compared with those with mild, moderate, or severe atrophy (23% vs 63%, 69%, and 87%, respectively).
CONCLUSIONS: Visual ratings of HPC and ERC provide useful information to a physician in a clinical setting. Visual ratings of ERC may be especially useful in following patients with MCI.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Alzheimer's; MCI; MRI; atrophy; entorhinal cortex; hippocampus

Mesh:

Year:  2014        PMID: 24816477     DOI: 10.1002/gps.4126

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  16 in total

1.  Translation of imaging biomarkers from clinical research to healthcare.

Authors:  Ingo Kilimann; Jochen René Thyrian; Wolfgang Hoffmann; Stefan J Teipel
Journal:  Z Gerontol Geriatr       Date:  2017-04-12       Impact factor: 1.281

2.  Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.

Authors:  David A Wolk; Carl Sadowsky; Beth Safirstein; Juha O Rinne; Ranjan Duara; Richard Perry; Marc Agronin; Jose Gamez; Jiong Shi; Adrian Ivanoiu; Lennart Minthon; Zuzana Walker; Steen Hasselbalch; Clive Holmes; Marwan Sabbagh; Marilyn Albert; Adam Fleisher; Paul Loughlin; Eric Triau; Kirk Frey; Peter Høgh; Andrea Bozoki; Roger Bullock; Eric Salmon; Gillian Farrar; Christopher J Buckley; Michelle Zanette; Paul F Sherwin; Andrea Cherubini; Fraser Inglis
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

Review 3.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

4.  Predictive Utility of Marketed Volumetric Software Tools in Subjects at Risk for Alzheimer Disease: Do Regions Outside the Hippocampus Matter?

Authors:  T P Tanpitukpongse; M A Mazurowski; J Ikhena; J R Petrella
Journal:  AJNR Am J Neuroradiol       Date:  2017-01-05       Impact factor: 3.825

5.  Predictive Scale for Amyloid PET Positivity Based on Clinical and MRI Variables in Patients with Amnestic Mild Cognitive Impairment.

Authors:  Min Young Chun; Geon Ha Kim; Hee Kyung Park; Dong Won Yang; SangYun Kim; Seong Hye Choi; Jee Hyang Jeong
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

6.  The correlation of everyday cognition test scores and the progression of Alzheimer's disease: a data analytics study.

Authors:  Fadi Thabtah; Robinson Spencer; Yongsheng Ye
Journal:  Health Inf Sci Syst       Date:  2020-07-23

7.  Entorhinal Cortex Thickness across the Human Lifespan.

Authors:  Khader M Hasan; Benson Mwangi; Bo Cao; Zafer Keser; Nicholas J Tustison; Peter Kochunov; Richard E Frye; Mirjana Savatic; Jair Soares
Journal:  J Neuroimaging       Date:  2015-10-08       Impact factor: 2.486

8.  Association of Homocysteine Levels With Medial Temporal Lobe Atrophy Among Carriers and Non-carriers of APOE ε4 in MCI Subjects.

Authors:  Jun Ma; Ling-Yun Ma; FengYuan Man; Guili Zhang
Journal:  Front Psychiatry       Date:  2022-04-12       Impact factor: 5.435

9.  Posterior Atrophy and Medial Temporal Atrophy Scores Are Associated with Different Symptoms in Patients with Alzheimer's Disease and Mild Cognitive Impairment.

Authors:  Jung-Lung Hsu; Wei-Ju Lee; Yi-Chu Liao; Jiing-Feng Lirng; Shuu-Jiun Wang; Jong-Ling Fuh
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

10.  Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging.

Authors:  Jamila Ahdidan; Cyrus A Raji; Edgar A DeYoe; Jedidiah Mathis; Karsten Ø Noe; Jens Rimestad; Thomas K Kjeldsen; Jesper Mosegaard; James T Becker; Oscar Lopez
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.